Messenger RNA (mRNA) based therapeutics in transforming cardiovascular care: Progress, regulatory challenges and future perspectives

被引：0

作者：

Khan, Mudassir ^{[1
,2
]}

Musazzi, Umberto M. ^{[3
]}

Manellari, Sara ^{[3
]}

Mouawad, Nayla ^{[2
]}

Damiano, Giulia ^{[2
]}

Rinaldi, Raffaella ^{[2
]}

Raucci, Angela ^{[2
]}

Costantino, Sarah ^{[4
,5
]}

Paneni, Francesco ^{[4
,5
]}

Minghetti, Paola ^{[3
]}

Pompilio, Giulio ^{[1
,2
]}

Vinci, Maria Cristina ^{[2
]}

机构：

[1] Univ Milan, Dept Biomed Surg & Dent Sci, I-20100 Milan, Italy

[2] Ctr Cardiol Monzino IRCCS, Via C Parea 4, I-20138 Milan, Italy

[3] Univ Milan, Dept Pharmaceut Sci, I-20133 Milan, Italy

[4] Univ Hosp Zurich, Univ Heart Ctr, Zurich, Switzerland

[5] Univ Zurich, Ctr Translat & Expt Cardiol CTEC, Dept Cardiol, Zurich, Switzerland

来源：

PHARMACOLOGICAL RESEARCH | 2025年 / 218卷

关键词：

mRNA-based therapeutics; Cardiovascular diseases (CVD); mRNA delivery systems; Regenerative medicine; Regulatory affairs; IMPROVES CARDIAC-FUNCTION; MYOCARDIAL BLOOD-FLOW; FUNCTIONAL RECOVERY; RIBOSOMAL-PROTEINS; VEGF-A; DELIVERY; NANOPARTICLES; MECHANISMS; EXPRESSION; VACCINES;

D O I：

10.1016/j.phrs.2025.107847

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Messenger RNA (mRNA) is emerging as a new tool for therapeutic intervention, providing a transient, programmable platform for the treatment of complex diseases. Unlike DNA-based therapies, mRNA does not integrate into the genome and is considered more safe. The success of mRNA vaccines, combined with advances in mRNA technology and unmet needs in cardiovascular disease (CVD), has led to increased interest in expanding the use of this technology beyond infectious diseases. However, there are several challenges to overcome, including mRNA stability, delivery efficiency, immunogenicity, and regulatory standardization. This review examines advances in mRNA design, delivery platforms, and therapeutic applications in CVDs, emphasizing the need for a clear regulatory framework to facilitate clinical translation. The establishment of consistent regulatory guidelines will be a critical step in ensuring the safety and efficacy of mRNA-based cardiovascular therapies, potentially facilitating their widespread adoption. The future direction of research in mRNA formulation, personalized medicine approaches, and the refinement of regulatory policies will determine the landscape of next-generation cardiovascular therapeutics.

引用

页数：15

共 223 条

[11] mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions [J].

Bakos, Tamas ;

Meszaros, Tamas ;

Kozma, Gergely Tibor ;

Berenyi, Petra ;

Facsko, Reka ;

Farkas, Henriette ;

Dezsi, Laszlo ;

Heirman, Carlo ;

de Koker, Stefaan ;

Schiffelers, Raymond ;

Glatter, Kathryn Anne ;

Radovits, Tamas ;

Szenasi, Gabor ;

Szebeni, Janos .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)

[12] The clinical progress of mRNA vaccines and immunotherapies [J].

Barbier, Ann J. ;

Jiang, Allen Yujie ;

Zhang, Peng ;

Wooster, Richard ;

Anderson, Daniel G. .

NATURE BIOTECHNOLOGY, 2022, 40 (06) :840-854

[13] Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting [J].

Barda, Noam ;

Dagan, Noa ;

Ben-Shlomo, Yatir ;

Kepten, Eldad ;

Waxman, Jacob ;

Ohana, Reut ;

Hernan, Miguel A. ;

Lipsitch, Marc ;

Kohane, Isaac ;

Netzer, Doron ;

Reis, Ben Y. ;

Balicer, Ran D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12) :1078-1090

[14] Implantable Devices: Issues and Challenges [J].

Bazaka, Kateryna ;

Jacob, Mohan V. .

ELECTRONICS, 2013, 2 (01) :1-34

[15] mRNA therapeutics in cancer immunotherapy [J].

Beck, Jan D. ;

Reidenbach, Daniel ;

Salomon, Nadja ;

Sahin, Ugur ;

Tureci, Ozlem ;

Vormehr, Mathias ;

Kranz, Lena M. .

MOLECULAR CANCER, 2021, 20 (01)

[16] Strategies to reduce the risks of mRNA drug and vaccine toxicity [J].

Bitounis, Dimitrios ;

Jacquinet, Eric ;

Rogers, Maximillian A. ;

Amiji, Mansoor M. .

NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (04) :281-300

[17] The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case [J].

Blenke, Erik Oude ;

Ornskov, Eivor ;

Schoneich, Christian ;

Nilsson, Gunilla A. ;

Volkin, David B. ;

Mastrobattista, Enrico ;

Almarsson, Orn ;

Crommelin, Daan J. A. .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (02) :386-403

[18] Monitoring mRNA vaccine antigen expression in vivo using PET/CT [J].

Blizard, Gabrielle S. ;

Dwivedi, Garima ;

Pan, Yi-Gen ;

Hou, Catherine ;

Etersque, Jean M. ;

Said, Hooda ;

Chevrier, Anik ;

Lavertu, Marc ;

Ni, Houping ;

Davis, Benjamin ;

Tam, Ying ;

Cao, Quy ;

Mach, Robert H. ;

Weissman, Drew ;

Alameh, Mohamad-Gabriel ;

Sellmyer, Mark A. .

NATURE COMMUNICATIONS, 2025, 16 (01)

[19] DIRECT COMPARISON OF [N-13] AMMONIA AND [O-15]WATER ESTIMATES OF PERFUSION WITH QUANTIFICATION OF REGIONAL MYOCARDIAL BLOOD-FLOW BY MICROSPHERES [J].

BOL, A ;

MELIN, JA ;

VANOVERSCHELDE, JL ;

BAUDHUIN, T ;

VOGELAERS, D ;

DEPAUW, M ;

MICHEL, C ;

LUXEN, A ;

LABAR, D ;

COGNEAU, M ;

ROBERT, A ;

HEYNDRICKX, GR ;

WIJNS, W .

CIRCULATION, 1993, 87 (02) :512-525

[20]

Bose R.J.C., 2017, Lipid-polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges, DOI [10.1016/j.drudis.2017.05.015, DOI 10.1016/J.DRUDIS.2017.05.015]

← 1 2 3 4 5 6 7 8 9 10 →